美國PrimCells誘導(dǎo)性穩(wěn)定細胞株： PrimCells建立的獨有的誘導(dǎo)性細胞高效開發(fā)系統(tǒng)，能在極短時間內(nèi)篩選出低泄漏，高誘導(dǎo)性的穩(wěn)定細胞株，成功開發(fā)出一系列核受體誘導(dǎo)表達的穩(wěn)定細胞株產(chǎn)品，為多家知名制藥公司研發(fā)部門和科研院所提供產(chǎn)品與服務(wù)，廣受用戶好評。針對客戶的特定需求，PrimCells亦提供量身定制服務(wù)，通過密切的客戶交流和高效的篩選體系，嚴格保證客戶在3-4周內(nèi)即獲得高質(zhì)量的誘導(dǎo)性穩(wěn)定細胞株，具有市場其他供應(yīng)商無可比擬的時效性。
Introduction:
Nuclear hormone receptors (NHRs) are a superfamily of transcription factors that function as powerful metabolic regulators to control a variety of systemic processes in physiology. They also play key roles in the pathophysiology of many major disease states, such as diabetes, obesity, inflammation, atherosclerosis and heart failure. To date, this superfamily has provided a rich source of drug design targets and it is continuing to be one of the hottest areas for pharmaceutical researches.
PrimCells now provides a comprehensive set of NHR expressing cell lines to the research community. These high-quality, flag-and/or HA-tagged NHR-expressing cell lines aim to facilitate further biochemical and molecular studies of their functions and hence encourage new strategies for drug design.
The mouse Nurr1 stable cell line was created by stable co-transfection of HEK293 cells with two plasmids expressing the bacterial Tet repressor (TetR) and the mouse Nurr1 protein with FLAG tag, respectively. Since the mouse Nurr1 gene is driven by a promoter containing two tetracycline operator (TeTO2) sites, its expression can be induced by doxycycline.
美國PrimCells品牌介紹
PrimCells是位于美國加州圣迭戈的一家專業(yè)致力于細胞產(chǎn)品研發(fā)和解決方案提供的業(yè)內(nèi)技術(shù)領(lǐng)導(dǎo)企業(yè)。
公司匯集了**的生物醫(yī)藥技術(shù)專家，獨立開發(fā)了多項原代細胞和干細胞相關(guān)的專有技術(shù)。 公司以“細胞研究的選擇”為宗旨，自主研發(fā)超過70種**產(chǎn)品，填補了多個特種細胞市場的空白。例如其誘導(dǎo)性表達細胞庫和高效3D皮膚培養(yǎng)系統(tǒng)，皆為該類產(chǎn)品目前市場上少數(shù)的規(guī)模化供應(yīng)商。此外，公司以高質(zhì)量的數(shù)據(jù)與快速穩(wěn)定的項目完成時間，長期為多家知名制藥公司提供解決方案，獲得用戶廣泛贊譽。
PrimCells產(chǎn)品線：
4. 人源重組蛋白 5. **型培養(yǎng)試劑
PrimCells 解決方案
1.誘導(dǎo)性穩(wěn)定細胞株開發(fā) 2. 原代細胞開發(fā) 3. **體外毒理和效能測試 4. 3D-皮膚培養(yǎng)
PrimCells合作伙伴及客戶:
A．生物制藥公司：輝瑞(Pfizer), 諾華(Novartis), 禮來(Eli2 Lilly),. Amgen, EMD Millipore, Regeneron等公司的毒理和醫(yī)藥研發(fā)部門
B．科研機構(gòu)：冷泉港實驗室，哈佛醫(yī)學(xué)院, 麻省理工（MIT）,， UCSF, NYU, Salk, UIUC, USC等
